Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
- PMID: 28495497
- DOI: 10.1016/j.jaad.2017.01.037
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Abstract
Background: Patients with psoriasis on biologic therapies and a history of viral hepatitis carry a risk for reactivation.
Objective: We evaluated safety of biologic therapies in psoriasis patients seropositive for hepatitis B or C viruses (HBV, HCV).
Methods: A retrospective cohort study design was used. Clinical and laboratory data for 30 patients undergoing biologic therapy who were seropositive for HBV or HCV were evaluated. Next, a systematic review was performed. Primary outcomes were hepatitis and viral reactivation during therapy. Treatment duration and antiviral prophylaxis were also recorded.
Results: Serology indicated HCV infection in 4 patients, past HBV infection in 17 patients, isolated core antibody in 8 patients, and chronic HBV infection in 1 patient. During follow-up (mean 4.85 ± 3.1 years), no patients experienced hepatitis or viral reactivation. The systematic review of the literature included 49 studies comprising 312 patients followed for a mean of 30.9 months. Viral reactivation occurred in 2/175 patients who were seropositive for core antibody and 3/97 with HCV infection (yearly rates, 0.32% and 2.42%, respectively) compared with 8/40 patients with chronic HBV infection (yearly rate, 13.92%). Three of these 8 patients with reactivated HBV infection received antiviral prophylaxis.
Limitations: We pooled heterogeneous studies evaluating different biologic therapies.
Conclusion: Biologic therapies pose minimal risk for viral reactivation in low-risk patients without hepatitis seropositive for HCV or HBV core antibody but are a considerable risk in patients with chronic HBV infection, highlighting the necessity of antiviral prophylaxis.
Keywords: HBcAg; biologic; hepatitis B virus; hepatitis C virus; psoriasis; reactivation; risk.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Risk of HBV reactivation in psoriasis vulgaris patients receiving biological agent therapy.Cutan Ocul Toxicol. 2025 Mar;44(1):113-117. doi: 10.1080/15569527.2025.2475444. Epub 2025 Mar 8. Cutan Ocul Toxicol. 2025. PMID: 40056433
-
Clinical Observational Study on HBV Reactivation After Direct-Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China.J Viral Hepat. 2025 Sep;32(9):e70061. doi: 10.1111/jvh.70061. J Viral Hepat. 2025. PMID: 40767547
-
Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis.Clin Exp Med. 2023 Jul;23(3):701-715. doi: 10.1007/s10238-022-00827-y. Epub 2022 Apr 30. Clin Exp Med. 2023. PMID: 35499793
-
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-180. doi: 10.1016/S2468-1253(18)30002-5. Epub 2018 Jan 19. Lancet Gastroenterol Hepatol. 2018. PMID: 29371017
-
Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis.Viruses. 2024 Dec 30;17(1):42. doi: 10.3390/v17010042. Viruses. 2024. PMID: 39861831 Free PMC article.
Cited by
-
Infections in the era of immunobiologicals.An Bras Dermatol. 2024 Mar-Apr;99(2):167-180. doi: 10.1016/j.abd.2023.08.004. Epub 2024 Jan 17. An Bras Dermatol. 2024. PMID: 38238209 Free PMC article.
-
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study.Dermatol Ther (Heidelb). 2022 May;12(5):1263-1270. doi: 10.1007/s13555-022-00726-w. Epub 2022 Apr 22. Dermatol Ther (Heidelb). 2022. PMID: 35460018 Free PMC article.
-
Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis.Clin Epidemiol. 2020 Feb 12;12:153-161. doi: 10.2147/CLEP.S239511. eCollection 2020. Clin Epidemiol. 2020. PMID: 32104099 Free PMC article.
-
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.Psoriasis (Auckl). 2025 Apr 11;15:127-144. doi: 10.2147/PTT.S510141. eCollection 2025. Psoriasis (Auckl). 2025. PMID: 40237012 Free PMC article. Review.
-
Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases.J Clin Med. 2021 Nov 8;10(21):5201. doi: 10.3390/jcm10215201. J Clin Med. 2021. PMID: 34768721 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous